CAR T cell immunotherapy for human cancer

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia

Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849

Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia

Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509

Cancer regression in patients after transfer of genetically engineered lymphocytes

Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

Morgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,564

Adoptive cell transfer as personalized immunotherapy for human cancer

Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,545

T cell exclusion, immune privilege, and the tumor microenvironment

Joyce, J. A., & Fearon, D. T. (2015) · Science · doi:10.1126/science.aaa6204 · Cited by 2,539

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

Kalos, M. D., Levine, B. L., Porter, D. L., Katz, S. I., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,417

Current Status of Immunotherapies for Treating Pancreatic Cancer

Wu, A. A., Jaffee, E. M., & Lee, V. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0811-5 · Cited by 47

Conventional CARs versus modular CARs

Feldmann, A., Arndt, C., Koristka, S., Berndt, N., Bergmann, R., & Bachmann, M. P. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02399-5 · Cited by 46

Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial

Maziarz, R. T., Schuster, S. J., Romanov, V. V., Rusch, E. S., Li, J., Signorovitch, J., Maloney, D. G., & Locke, F. L. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001305 · Cited by 45

Chemically Programmable and Switchable CAR‐T Therapy

Qi, J., Tsuji, K., Hymel, D., Burke, T. R., Hudecek, M., Rader, C. M., & Peng, H. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202005432 · Cited by 45

License to Kill: When iNKT Cells Are Granted the Use of Lethal Cytotoxicity

Díaz‐Basabe, A., Strati, F., & Facciotti, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113909 · Cited by 45

Nanomaterials as Smart Immunomodulator Delivery System for Enhanced Cancer Therapy

Yuan, C.-S., Liu, Y., Wang, T., Sun, M., & Chen, X. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c00804 · Cited by 45

PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells.

Liu, G.-D., Zhang, Q., Li, D., Zhang, L.-S., Gu, Z., Liu, J., Liu, G.-P., Yang, M., Gu, J., Cui, X., et al. (2020) · Human Immunology · doi:10.1016/j.humimm.2020.12.002 · Cited by 40

High-Throughput Screening for Drug Discovery

Saxena, S. K. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.91075 · Cited by 46

Immunotherapies for pediatric cancer: current landscape and future perspectives

Hutzen, B., Paudel, S. N., Naeimi Kararoudi, M., Cassady, K. A., Lee, D. A., & Cripe, T. P. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09819-z · Cited by 44

Injectable Porous Microchips with Oxygen Reservoirs and an Immune-Niche Enhance the Efficacy of CAR T Cell Therapy in Solid Tumors

Luo, Z., Liu, Z., Liang, Z., Pan, J., Xu, J., Dong, J., Bai, Y., Deng, H., & Wei, S. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c15239 · Cited by 44

Early diagnosis and therapeutic strategies for hepatocellular carcinoma: From bench to bedside

Guan, M., Wang, M.-D., Liu, S., Ouyang, W., Liang, L., Pawlik, T. M., Xu, Q., Huang, D., Shen, F., Zhu, H., et al. (2021) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v13.i4.197 · Cited by 48

Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data

Li, M., Gao, X., & Wang, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1090838 · Cited by 52

Cell metabolism-based optimization strategy of CAR-T cell function in cancer therapy

Li, W., Pan, X., Chen, L., Cui, H., Mo, S., Pan, Y., Shen, Y., Shi, M., Wu, J., Luo, F., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1186383 · Cited by 49

Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management

Allemailem, K. S., Alsahli, M. A., Almatroudi, A., Alrumaihi, F., Abdulmonem, W. A., Moawad, A. A., Alwanian, W. M., Almansour, N. M., Rahmani, A. H., & Khan, A. A. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s424872 · Cited by 49

The Role of Tumor Metabolic Reprogramming in Tumor Immunity

Zhang, X., Song, W., Gao, Y., Zhang, Y., Zhao, Y., Hao, S., & Ni, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417422 · Cited by 48

Activating CD8+ T Cells by Pt(IV) Prodrug‐Based Nanomedicine and aPD‐L1 Antibody for Enhanced Cancer Immunotherapy

Wang, B., Zhou, J., Li, R., Tang, D., Cao, Z., Xu, C., & Xiao, H. (2024) · Advanced Materials · doi:10.1002/adma.202311640 · Cited by 44

T-Cell Receptor–Based Immunotherapy for Hematologic Malignancies

Biernacki, M. A., Brault, M., & Bleakley, M. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000378 · Cited by 46

NKG2D Controls Natural Reactivity of Vγ9Vδ2 T Lymphocytes against Mesenchymal Glioblastoma Cells

Chauvin, C., Joalland, N., Perroteau, J., Jarry, U., Lafrance, L., Willem, C., Retière, C., Oliver, L., Gratas, C., Gautreau‐Rolland, L., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0375 · Cited by 47

Imaging of cell-based therapy using 89Zr-oxine ex vivo cell labeling for positron emission tomography

Kurebayashi, Y., Choyke, P. L., & Sato, N. (2020) · Nanotheranostics · doi:10.7150/ntno.51391 · Cited by 45

Engineering in vitro immune-competent tissue models for testing and evaluation of therapeutics

Hammel, J. H., Zatorski, J. M., Cook, S. R., Pompano, R. R., & Munson, J. M. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114111 · Cited by 42

CRISPR/Cas9 application in cancer therapy: a pioneering genome editing tool

Baghini, S. S., Gardanova, Z. R., Abadi, S. A. H., Zaman, B. A., İlhan, A., Shomali, N., Adili, A., Moghaddar, R., & Yaseri, A. F. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00336-6 · Cited by 46

CRISPR-Cas System: The Current and Emerging Translational Landscape

Bhokisham, N., Laudermilch, E., Traeger, L. L., Bonilla, T. D., Ruíz-Estévez, M., & Becker, J. R. (2023) · Cells · doi:10.3390/cells12081103 · Cited by 46

Mesenchymal stromal cells with chimaeric antigen receptors for enhanced immunosuppression

Sirpilla, O. L., Sakemura, R. L., Hefazi, M., Huynh, T., Can, İ., Girsch, J. H., Tapper, E. E., Cox, M. J., Schick, K. J., Manriquez-Roman, C., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01195-6 · Cited by 43

Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again

Bucktrout, S. L., Bluestone, J. A., & Ramsdell, F. (2018) · Genome Medicine · doi:10.1186/s13073-018-0588-4 · Cited by 47

Identification of gene expression profiles and immune cell infiltration signatures between low and high tumor mutation burden groups in bladder cancer

Wu, Z., Wang, M.-R., Liu, Q., Liu, Y., Zhu, K., Chen, L., Guo, H., Li, Y., & Shi, B. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.39056 · Cited by 43

Improving safety of cancer immunotherapy via delivery technology

Hu, D., Zhang, W., Tang, J., Zhou, Z., Liu, X., & Shen, Y. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120407 · Cited by 43

Pathogenesis of chronic lymphocytic leukemia and the development of novel therapeutic strategies

Kikushige, Y. (2020) · Journal of the Japan Society of the Reticuloendothelial System · doi:10.3960/jslrt.20036 · Cited by 48

Universal toxin-based selection for precise genome engineering in human cells

Li, S., Akrap, N., Cerboni, S., Porritt, M. J., Wimberger, S., Lundin, A., Möller, C., Firth, M. A., Gordon, E., Lazovic, B., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20810-z · Cited by 46

Lighting up the fire in the microenvironment of cold tumors: a major challenge to improve cancer immunotherapy

Benoit, A., Vogin, G., Duhem, C., Berchem, G., & Janji, B. (2023) · Cells · doi:10.3390/cells12131787 · Cited by 39

A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis

Vreeland, T. J., Clifton, G. T., Hale, D. F., Chick, R. C., Hickerson, A. T., Cindass, J. L., Adams, A. M., Bohan, P. M. K., Andtbacka, R. H. I., Berger, A. C., et al. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-09709-1 · Cited by 46

Emerging Biomaterials Imaging Antitumor Immune Response

Ma, X., Zhang, M., Wang, J., Zhang, T., Xue, P., Kang, Y., Sun, Z., & Xu, Z. (2022) · Advanced Materials · doi:10.1002/adma.202204034 · Cited by 42

Microneedle-based cell delivery and cell sampling for biomedical applications

Mbituyimana, B., Adhikari, M., Qi, F., Shi, Z., Fu, L., & Yang, G. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.013 · Cited by 43

CD8-Targeted IL2 Unleashes Tumor-Specific Immunity in Human Cancer Tissue by Reviving the Dysfunctional T-cell Pool

Kaptein, P., Slingerland, N., Metoikidou, C., Prinz, F., Brokamp, S., Machuca-Ostos, M., de Roo, G., Schumacher, T. N., Yeung, Y. A., Moynihan, K. D., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1263 · Cited by 41

CAR-T Cells Therapy in Glioblastoma: A Systematic Review on Molecular Targets and Treatment Strategies

Agosti, E., Garaba, A., Antonietti, S., Ius, T., Fontanella, M. M., Zeppieri, M., & Panciani, P. P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137174 · Cited by 45

T cell exhaustion in human cancers

Kang, K., Lin, X., Chen, P., Liu, H., Liu, F., Xiong, W., Li, G., Yi, M., Li, X., Wang, H., et al. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189162 · Cited by 49

Fine Epitope Mapping of the CD19 Extracellular Domain Promotes Design

Klesmith, J. R., Wu, L., Lobb, R. R., Rennert, P. D., & Hackel, B. J. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00808 · Cited by 42

Nanotechnology Promotes Genetic and Functional Modifications of Therapeutic T Cells Against Cancer

Abdalla, A. M. E., Xiao, L. J., Miao, Y., Huang, L., Fadlallah, G. M., Gauthier, M., Ouyang, C., & Yang, G. (2020) · Advanced Science · doi:10.1002/advs.201903164 · Cited by 42

Nanoparticles weaponized with built‐in functions for imaging‐guided cancer therapy

Jing, L., Yang, C., Zhang, P., Zeng, J., Li, Z., & Gao, M. (2020) · Open Research (University of Surrey) · doi:10.1002/viw2.19 · Cited by 42

HIF1A expression correlates with increased tumor immune and stromal signatures and aggressive phenotypes in human cancers

Chen, B., Li, L., Li, M., & Wang, X. (2020) · Cellular Oncology · doi:10.1007/s13402-020-00534-4 · Cited by 41

Targeted Delivery of CXCL9 and OX40L by Mesenchymal Stem Cells Elicits Potent Antitumor Immunity

Yin, P., Gui, L., Wang, C., Yan, J., Liu, M., Ji, L., Wang, Y., Ma, B., & Gao, W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.08.005 · Cited by 44

Click CAR-T cell engineering for robustly boosting cell immunotherapy in blood and subcutaneous xenograft tumor

Pan, H., Li, W., Chen, Z., Luo, Y., He, W., Wang, M., Tang, X., He, H., Liu, L., Zheng, M., et al. (2020) · Bioactive Materials · doi:10.1016/j.bioactmat.2020.09.025 · Cited by 42

Intelligent stimuli-responsive nano immunomodulators for cancer immunotherapy

Li, Y., Zhang, X., Liu, X., Pan, W., Li, N., & Tang, B. (2021) · Chemical Science · doi:10.1039/d0sc06557a · Cited by 42

Engineered Cytokines for Cancer and Autoimmune Disease Immunotherapy

Uricoli, B., Birnbaum, L. A., Do, P., Kelvin, J., Jain, J., Costanza, E., Chyong, A., Porter, C. C., Rafiq, S., & Dreaden, E. C. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202002214 · Cited by 43

Exosomes: Powerful weapon for cancer nano-immunoengineering

Pi, Y., Xia, B.-R., Jin, M., Jin, W., & Lou, G. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114487 · Cited by 42

Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells

Lee, M. Y., Robbins, Y. L., Sievers, C. M., Friedman, J., Sater, H. A., Clavijo, P. E., Judd, N. P., Tsong, E., Silvin, C., Soon‐Shiong, P., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002128 · Cited by 43

Finding Solutions for Fibrosis: Understanding the Innate Mechanisms Used by Super‐Regenerator Vertebrates to Combat Scarring

Durant, F., & Whited, J. L. (2021) · Advanced Science · doi:10.1002/advs.202100407 · Cited by 43

Phototherapy Facilitates Tumor Recruitment and Activation of Natural Killer T cells for Potent Cancer Immunotherapy

Li, M., Xie, D., Tang, X., Chen, Y., Shen, Y., Zhou, H., Deng, W., Liu, J., Cai, S., Bai, L., et al. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c02238 · Cited by 42

A cascade targeting strategy based on modified bacterial vesicles for enhancing cancer immunotherapy

Zhai, Y., Ma, Y., Pang, B., Zhang, J., Li, Y., Rui, Y., Xu, T., Zhao, Y., Qian, Z., Gu, Y., et al. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01193-9 · Cited by 41

Mechano-modulation of T cells for cancer immunotherapy

Hyun, J., Kim, S. J., Cho, S., & Kim, H. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122101 · Cited by 40

Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1

Mun, S. S., Meyerberg, J., Peraro, L., Korontsvit, T., Gardner, T. J., Malviya, M., Kyi, C., O'Cearbhaill, R. E., Liu, C., Dao, T., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03529-w · Cited by 42

The immunoglobulin superfamily ligand B7H6 subjects T cell responses to NK cell surveillance

Kilian, M., Friedrich, M., Lu, K. H.-N., Vonhören, D., Jansky, S., Michel, J., Keib, A., Stange, S., Hackert, N. S., Kehl, N., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adj7970 · Cited by 43

Bispecific CAR-T cells targeting FAP and GPC3 have the potential to treat hepatocellular carcinoma

Zhou, L., Li, Y., Zheng, D., Zheng, Y., Cui, Y., Qin, L., Tang, Z., Peng, D., Wu, Q., Long, Y., et al. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200817 · Cited by 47

Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia

Liu, D., Zhao, J., Song, Y., Luo, X., & Yang, T. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0703-z · Cited by 41

Common gamma chain cytokines and CD8 T cells in cancer

Shourian, M., Beltra, J., Bourdin, B., & Decaluwe, H. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101307 · Cited by 43

Adult and Cord Blood-Derived High-Affinity gB-CAR-T Cells Effectively React Against Human Cytomegalovirus Infections

Olbrich, H., Theobald, S. J., Slabik, C., Gerasch, L., Schneider, A., Mach, M., Shum, T., Mamonkin, M., & Stripecke, R. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.149 · Cited by 46

Anti-glycan antibodies: roles in human disease

Temme, J. S., Butler, D. L., & Gildersleeve, J. C. (2021) · Biochemical Journal · doi:10.1042/bcj20200610 · Cited by 43

Insights Into Dendritic Cells in Cancer Immunotherapy: From Bench to Clinical Applications

Salah, A., Wang, H., Li, Y., Ji, M., Ou, W., Qi, N., & Wu, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.686544 · Cited by 44

Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma

Zhang, L., Shen, X., Yu, W., Li, J., Zhang, J., Zhang, R., Li, J., & Chen, L. (2021) · Annals of Medicine · doi:10.1080/07853890.2021.1970218 · Cited by 41

Single-cell profiling of infiltrating B cells and tertiary lymphoid structures in the TME of gastric adenocarcinomas

Jia, L., Wang, T., Zhao, Y., Zhang, S., Ba, T., Kuai, X., Wang, B., Zhang, N., Zhao, W., Yang, Z., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1969767 · Cited by 42

Immunomodulatory effect of locoregional therapy in the tumor microenvironment

Xie, L., & Meng, Z. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.01.017 · Cited by 41

“Stapling” scFv for multispecific biotherapeutics of superior properties

Boucher, L., Prinslow, E. G., Feldkamp, M. D., Yi, F., Nanjunda, R. K., Wu, S., Liu, T., Lacy, E. R., Jacobs, S., Kozlyuk, N., et al. (2023) · mAbs · doi:10.1080/19420862.2023.2195517 · Cited by 40

Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy

Marone, R., Landmann, E., Devaux, A., Lepore, R., Seyres, D., Zuin, J., Burgold, T., Engdahl, C., Capoferri, G., Dell’Aglio, A., et al. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20231235 · Cited by 39

CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond

Mishra, A. K., Gupta, A., Dagar, G., Das, D., Chakraborty, A., Haque, S., Prasad, C. P., Singh, A. K., Bhat, A. A., Macha, M. A., et al. (2023) · Vaccines · doi:10.3390/vaccines11111721 · Cited by 40

CAR-T Cell Therapy in Ovarian Cancer: Where Are We Now?

Cutri‐French, C., Nasioudis, D., George, E. M., & Tanyi, J. L. (2024) · Diagnostics · doi:10.3390/diagnostics14080819 · Cited by 40

Enhancing Glioblastoma Immunotherapy with Integrated Chimeric Antigen Receptor T Cells through the Re-Education of Tumor-Associated Microglia and Macrophages

Zhu, N., Chen, S., Jin, Y., Wang, M., Fang, L., Xue, L., Hua, D., Zhang, Z., Jia, M., Hao, M., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c00050 · Cited by 43

Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: a systematic review

Kattamuri, L. P. V., Lal, B. M., Vojjala, N., Jain, M., Sharma, K., Jain, S., & Hadidi, S. A. (2025) · Rheumatology International · doi:10.1007/s00296-024-05772-5 · Cited by 40

Integrated computational analysis identifies therapeutic targets with dual action in cancer cells and T cells

Luo, C., Zhang, R., Guo, R., Wu, L., Xue, T., He, Y., Jin, Y., Zhao, Y., Zhang, Z., Zhang, P., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.02.007 · Cited by 37

Two-in-One Platform for High-Efficiency Intracellular Delivery and Cell Harvest: When a Photothermal Agent Meets a Thermoresponsive Polymer

Wu, J., Zheng, Y., Jiang, S., Qu, Y., Wei, T., Zhan, W., Wang, L., Yu, Q., & Chen, H. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b01586 · Cited by 41

Intrinsic cancer vaccination

Yang, Y., Nam, G., Kim, G. B., Kim, Y. K., & Kim, I. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.05.007 · Cited by 40

Structure-based rational design of a novel chimeric PD1-NKG2D receptor for natural killer cells

Guo, C., Wang, X., Zhang, H., Zhi, L., Lv, T., Li, M., Lu, C., & Zhu, W. (2019) · Molecular Immunology · doi:10.1016/j.molimm.2019.07.009 · Cited by 40

Single-Cell Multiplexed Proteomics on the IsoLight Resolves Cellular Functional Heterogeneity to Reveal Clinical Responses of Cancer Patients to Immunotherapies

Liu, D., Paczkowski, P., Mackay, S., Ng, C., & Zhou, J. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9773-2_19 · Cited by 40

Surface-Mediated Intracellular Delivery by Physical Membrane Disruption

Qu, Y., Zhang, Y., Yu, Q., & Chen, H. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c06978 · Cited by 40

Immunotherapy in Advanced Biliary Tract Cancers

Boilève, A., Hilmi, M., Smolenschi, C., Ducreux, M. P., Hollebecque, A., & Malka, D. (2021) · Cancers · doi:10.3390/cancers13071569 · Cited by 41

Activation of invariant natural killer T cells stimulates adipose tissue remodeling via adipocyte death and birth in obesityPreprint

Park, J., Huh, J. Y., Oh, J., Kim, J. I., Han, S. M., Shin, K. C., Jeon, Y. G., Choe, S. S., Park, J., & Kim, J. B. (2019) · Genes & Development · doi:10.1101/gad.329557.119 · Cited by 41

Novel cellular immunotherapy using NKG2D CAR-T for the treatment of cervical cancer

Zhang, Y., Li, X., Zhang, J., & Mao, L. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110562 · Cited by 39

ROR1-targeting switchable CAR-T cells for cancer therapy

Peng, H., Nerreter, T., Mestermann, K., Wachter, J., Chang, J., Hudecek, M., & Rader, C. M. (2022) · Oncogene · doi:10.1038/s41388-022-02416-5 · Cited by 38

The tumor microenvironment of hepatocellular carcinoma and its targeting strategy by CAR-T cell immunotherapy

Zhang, G., Guanchang, J., Liwen, L., Huifen, W., Zhigang, R., Ranran, S., & Yu, Z. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.918869 · Cited by 39

Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies

Turpin, A., Neuzillet, C., Colle, E., Dusetti, N., Nicolle, R., Cros, J. F., de Mestier, L., Bachet, J., & Hammel, P. R. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221118019 · Cited by 41

CAR-T Therapy in GBM: Current Challenges and Avenues for Improvement

Pant, A., & Lim, M. K. (2023) · Cancers · doi:10.3390/cancers15041249 · Cited by 39

Cancer immunotherapies: A hope for the uncurable?

Hamdan, F., & Cerullo, V. (2023) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2023.1140977 · Cited by 41

Leptomeningeal dissemination in pediatric brain tumors

Cocito, C., Martin, B., Giantini-Larsen, A., Valcarce‐Aspegren, M., Souweidane, M. M., Szalontay, L., Dahmane, N., & Greenfield, J. P. (2023) · Neoplasia · doi:10.1016/j.neo.2023.100898 · Cited by 41

The Interplay between T Cells and Cancer: The Basis of Immunotherapy

Chen, C., Liu, X., Chang, C., Wang, H. Y., & Wang, R. (2023) · Genes · doi:10.3390/genes14051008 · Cited by 42

Cellular and molecular imaging of CAR-T cell-based immunotherapy

Liu, L., Yoon, C. W., Yuan, Z., Guo, T., Qu, Y., He, P., Yu, X., Zhu, Z., Limsakul, P., & Wang, Y. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115135 · Cited by 41

Modifying CAR-T cells with anti-checkpoints in cancer immunotherapy: A focus on anti PD-1/PD-L1 antibodies

Najafi, S., & Mortezaee, K. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122387 · Cited by 39

A Roadmap of CAR-T-Cell Therapy in Glioblastoma: Challenges and Future Perspectives

Montoya, M., Gallus, M., Phyu, S. M., Haegelin, J., de Groot, J., & Okada, H. (2024) · Cells · doi:10.3390/cells13090726 · Cited by 43

Antigen-specific immunotherapies for autoimmune disease

Buckner, J. H. (2024) · Nature Reviews Rheumatology · doi:10.1038/s41584-024-01201-w · Cited by 41

CAR T cells in autoimmunity: game changer or stepping stone?

Mougiakakos, D., Meyer, E. H., & Schett, G. A. (2024) · Blood · doi:10.1182/blood.2024025413 · Cited by 39

Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and Oncology

Zhang, C., Ötjengerdes, R., Roewe, J., Mejı́as, R., & Marschall, A. L. J. (2020) · BioDrugs · doi:10.1007/s40259-020-00419-w · Cited by 44

Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFNγ/CXCL10-dependent peripheral T cell recruitment in humanized murine model

Cremasco, F., Menietti, E., Speziale, D., Sam, J., Sammicheli, S., Richard, M., Varol, A., Klein, C., Umaña, P., Bacac, M., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0241091 · Cited by 40

The role of LncRNAs in tumor immunotherapy

Pan, X., Li, C., & Feng, J. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02872-3 · Cited by 40

Engineered in vitro tumor models for cell-based immunotherapy

Ando, Y., Mariano, C. F., & Shen, K. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.03.076 · Cited by 38

Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies

Poussin, M., Sereno, A., Wu, X., Huang, F., Manro, J. R., Cao, S., Carpenito, C., Glasebrook, A. L., Powell, D. J., & Demarest, S. J. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002444 · Cited by 38

High-Throughput and Efficient Intracellular Delivery Method via a Vibration-Assisted Nanoneedle/Microfluidic Composite System

Li, X., Ma, Y., Yu, X., Zhang, X., Lv, L., Quan, Q., Chen, Y., Yu, G., Liang, Z., Zhang, X., et al. (2022) · ACS Nano · doi:10.1021/acsnano.2c07852 · Cited by 41

Progression in immunotherapy for advanced prostate cancer

Liang, H., Liu, Y., Guo, J., Dou, M., Zhang, X., Hu, L., & Chen, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1126752 · Cited by 40

Deciphering the complexities of cancer cell immune evasion: Mechanisms and therapeutic implications

Gupta, I., Hussein, O., Sastry, K. S., Bougarn, S., Gopinath, N., Chin-Smith, E. C., Sinha, Y., Korashy, H. M., & Maccalli, C. (2023) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2023.100107 · Cited by 39

CAR-NK cells in combination therapy against cancer: A potential paradigm

Li, J., Hu, H., Lian, K., Zhang, D., Hu, P., He, Z., Zhang, Z., & Wang, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27196 · Cited by 40

Metabolic priming of GD2 TRAC-CAR T cells during manufacturing promotes memory phenotypes while enhancing persistence

Cappabianca, D., Pham, D. L., Forsberg, M. H., Bugel, M., Tommasi, A. M., Lauer, A. C., Vidugirienė, J., Hrdlicka, B., McHale, A., Sodji, Q. H., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101249 · Cited by 37

Overcoming Antigen Escape and T-Cell Exhaustion in CAR-T Therapy for Leukemia

Bartoszewska, E., Tota, M., Kisielewska, M., Skowron, I., Sebastianka, K., Stefaniak, O., Molik, K., Rubin, J., Kraska, K., & Choromańska, A. (2024) · Cells · doi:10.3390/cells13181596 · Cited by 41

Natural killer cell-based cancer immunotherapy: from basics to clinical trials

Shi, Y., Hao, D., Qian, H., & Tao, Z. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00561-z · Cited by 41

Myeloid effector cells in cancer

Schol, P. J., van Elsas, M. J., Middelburg, J., Twilhaar, M. K. N., van Hall, T., van der Sluis, T. C., & van der Burg, S. H. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.11.002 · Cited by 39

Trial Watch: Adoptive cell transfer for oncological indications

Aranda, F., Buqué, A., Bloy, N., Castoldi, F., Eggermont, A. M. M., Cremer, I., Fridman, W. H., Fucikova, J. P., Galon, J., Špíšek, R., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1046673 · Cited by 33

Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street

Barrett, D. M., Grupp, S. A., & June, C. H. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500751 · Cited by 182

Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer

Lundh, S. M., Jung, I.-Y., Dimitri, A. J., Vora, A., Melenhorst, J. J., Jadlowsky, J. K., & Fraietta, J. A. (2020) · Clinical and Experimental Medicine · doi:10.1007/s10238-020-00628-1 · Cited by 10

Improving cell reinfusion to enhance the efficacy of chimeric antigen receptor T-cell therapy and alleviate complications

Han, Z., Ma, X., & Ma, G. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28098 · Cited by 3

Abstract KN01: Updates on engineered T cells as cancer therapies

June, C. H. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-15-kn01